Targeting ischemic brain injury with intravenous immunoglobulin

Thiruma V. Arumugam; Pradeep K. Selvaraj; Trent M. Woodruff; Mark P. Mattson

doi:10.1517/14728222.12.1.19

Targeting ischemic brain injury with intravenous immunoglobulin

Thiruma V. Arumugam, Pradeep K. Selvaraj, Trent M. Woodruff, Mark P. Mattson

School of Medicine

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Background: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. Objective: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. Methods: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. Results/conclusion: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in human stroke patients are warranted.

Original language	English (US)
Pages (from-to)	19-29
Number of pages	11
Journal	Expert Opinion on Therapeutic Targets
Volume	12
Issue number	1
DOIs	https://doi.org/10.1517/14728222.12.1.19
State	Published - Jan 2008

Keywords

Apoptosis
Cerebral ischemia
Complement
Intravenous immunoglobulin
Ischemic stroke
T lymphocytes

ASJC Scopus subject areas

Molecular Medicine
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1517/14728222.12.1.19

Cite this

@article{ca3fbc096bb34d74b90390db87fee45a,

title = "Targeting ischemic brain injury with intravenous immunoglobulin",

abstract = "Background: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. Objective: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. Methods: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. Results/conclusion: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in human stroke patients are warranted.",

keywords = "Apoptosis, Cerebral ischemia, Complement, Intravenous immunoglobulin, Ischemic stroke, T lymphocytes",

author = "Arumugam, {Thiruma V.} and Selvaraj, {Pradeep K.} and Woodruff, {Trent M.} and Mattson, {Mark P.}",

year = "2008",

month = jan,

doi = "10.1517/14728222.12.1.19",

language = "English (US)",

volume = "12",

pages = "19--29",

journal = "Expert Opinion on Therapeutic Targets",

issn = "1472-8222",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Targeting ischemic brain injury with intravenous immunoglobulin

AU - Arumugam, Thiruma V.

AU - Selvaraj, Pradeep K.

AU - Woodruff, Trent M.

AU - Mattson, Mark P.

PY - 2008/1

Y1 - 2008/1

N2 - Background: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. Objective: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. Methods: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. Results/conclusion: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in human stroke patients are warranted.

AB - Background: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved for the treatment of autoimmune disorders. Objective: This review discusses how IVIG can prevent brain damage following ischemic stroke and discuss the potential mechanisms of action. Methods: Medline and the world wide web were searched and the relevant literature was classified under the following categories: IVIG, IVIG mechanism of action, and ischemic stroke injury mechanisms. Results/conclusion: Brain ischemia induces an inflammatory response that contributes to neuronal cell death. Because of its ability to block multiple molecular events, IVIG may have particularly strong neuroprotective action against ischemic brain injury. In light of the extensive clinical experience with IVIG for other indications, development of clinical trials to evaluate the use of IVIG in human stroke patients are warranted.

KW - Apoptosis

KW - Cerebral ischemia

KW - Complement

KW - Intravenous immunoglobulin

KW - Ischemic stroke

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=39049172669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049172669&partnerID=8YFLogxK

U2 - 10.1517/14728222.12.1.19

DO - 10.1517/14728222.12.1.19

M3 - Article

C2 - 18076367

AN - SCOPUS:39049172669

SN - 1472-8222

VL - 12

SP - 19

EP - 29

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

IS - 1

ER -

Targeting ischemic brain injury with intravenous immunoglobulin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this